osimertinib
astrazeneca
['maintain trial', 'ideal trial']
 now i understand and agree. ideal trial comparison would be osi at start vs placebo until progression, followed by osi at relapse. however, i see the difficulty in trial design, how do you crossover without unblinding if you intend to maintain trial integrity for pfs and os.
Biotech Pharma executive, Actor, Runner Apollomics Inc, President & CoFounder